Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candonilimab in Combination With LM-302 for Treatment of Patients With Claudin 18.2 Positive-advanced Biliary Tract Cancer
NCT05994001Phase 2Active, not recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2023
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab, tpx-4589 in biliary tract cancer (BTC), sponsored by Zhongshan Hospital, Fudan University. Started Aug 2023; status: active, not recruiting.
02
Drugs
cadonilimabtpx-4589
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05994001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05994001.